TY - JOUR AB - Ovarian cancer has the highest mortality rate among gynecological cancers; the most effective therapy for this cancer is a combination of radiation treatment and chemotherapy. However, radiation resistance is the leading factor associated with treatment failure. The present study aimed to investigate pseudolaric acid B (PAB) as a potential radiosensitizer for the treatment of ovarian cancer. The present study performed MTT and clonogenic assays, and demonstrated that PAB could induce a radiosensitizing effect on SKOV‑3 cells. An Annexin V/propidium iodide staining assay revealed that PAB exerted a radiosensitizing effect by inducing SKOV‑3 cell apoptosis. In addition, western blot analysis demonstrated that the activity of the Ras/RAF proto‑oncogene serine/threonine‑protein kinase/extracellular signal‑regulated kinase signaling pathway was reduced by combination therapy with PAB and irradiation. In conclusion, the present study establishes PAB as a radiosensitizer, and provides a rational basis for the use of PAB and irradiation as a combination therapy to treat ovarian cancer. AD - Department of Gynecological Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, Shandong 250117, P.R. China AU - Song,Quqing AU - Jiang,Sheng AU - Zhang,Xinxin AU - Pan,Chunxia AU - Lu,Chunhua AU - Peng,Jingwei AU - Li,Qingshui DA - 2018/01/01 DO - 10.3892/etm.2017.5500 EP - 690 IS - 1 JO - Exp Ther Med KW - pseudolaric acid B irradiation apoptosis ovarian cancer Ras‑Raf‑ERK signaling pathway radioresistance PY - 2018 SN - 1792-0981 1792-1015 SP - 685 ST - Radiosensitivity of human ovarian cancer cells is enhanced by pseudolaric acid B due to the inhibition of the Ras/Raf/ERK signaling pathway T2 - Experimental and Therapeutic Medicine TI - Radiosensitivity of human ovarian cancer cells is enhanced by pseudolaric acid B due to the inhibition of the Ras/Raf/ERK signaling pathway UR - https://doi.org/10.3892/etm.2017.5500 VL - 15 ER -